111 related articles for article (PubMed ID: 33186694)
1. Selenium-doped calcium phosphate biomineral reverses multidrug resistance to enhance bone tumor chemotherapy.
Hu J; Jiang Y; Tan S; Zhu K; Cai T; Zhan T; He S; Chen F; Zhang C
Nanomedicine; 2021 Feb; 32():102322. PubMed ID: 33186694
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-catalyzed synthesis of selenium-doped manganese phosphate for synergistic therapy of drug-resistant colorectal cancer.
Pei M; Liu K; Qu X; Wang K; Chen Q; Zhang Y; Wang X; Wang Z; Li X; Chen F; Qin H; Zhang Y
J Nanobiotechnology; 2023 Mar; 21(1):72. PubMed ID: 36859296
[TBL] [Abstract][Full Text] [Related]
3. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C
Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077
[TBL] [Abstract][Full Text] [Related]
4. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
[TBL] [Abstract][Full Text] [Related]
5. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
6. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
7. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
8. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
[TBL] [Abstract][Full Text] [Related]
9. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
10. Designed Synthesis of Lipid-Coated Polyacrylic Acid/Calcium Phosphate Nanoparticles as Dual pH-Responsive Drug-Delivery Vehicles for Cancer Chemotherapy.
Wang X; Zhang M; Zhang L; Li L; Li S; Wang C; Su Z; Yuan Y; Pan W
Chemistry; 2017 May; 23(27):6586-6595. PubMed ID: 28218434
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
12. In situ DOX-calcium phosphate mineralized CPT-amphiphilic gelatin nanoparticle for intracellular controlled sequential release of multiple drugs.
Li WM; Su CW; Chen YW; Chen SY
Acta Biomater; 2015 Mar; 15():191-9. PubMed ID: 25542535
[TBL] [Abstract][Full Text] [Related]
13. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
[TBL] [Abstract][Full Text] [Related]
15. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
[TBL] [Abstract][Full Text] [Related]
16. A newly synthesized nickel chelate can selectively target and overcome multidrug resistance in cancer through redox imbalance both in vivo and in vitro.
Banerjee K; Biswas MK; Choudhuri SK
J Biol Inorg Chem; 2017 Dec; 22(8):1223-1249. PubMed ID: 29063196
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
19. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
Wei G; Yang G; Wei B; Wang Y; Zhou S
Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
[TBL] [Abstract][Full Text] [Related]
20. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
